Literature DB >> 17135808

ADCS Prevention Instrument Project: behavioral measures in primary prevention trials.

Jeffrey L Cummings1, Rema Raman, Karin Ernstrom, David Salmon, Steven H Ferris.   

Abstract

BACKGROUND: There is an urgent need for the development of inexpensive, reliable, and valid instruments that can be used in large-scale primary prevention trials of compounds aimed at ameliorating progression from normal aging to mild cognitive impairment or Alzheimer disease. The Alzheimer's Disease Cooperative Study launched a Prevention Instrument Project to develop such methodologies. Behavioral changes are common in diseases causing dementia and may occur prior to a point when cognitive changes are sufficiently severe to allow diagnosis of a dementia syndrome. Experimental behavioral measures were included in the protocol to examine this hypothesis.
METHODS: Six hundred forty-four individuals with CDR 0 or 0.5 were randomly assigned to receive a brief in-clinic behavioral assessment or telephonic administration of the same assessment. The questions were asked to the individual and their research partner. The Prevention Instrument Project included behavioral measures of depression, anxiety, irritability, and apathy.
RESULTS: All measures demonstrated acceptable test-retest reliability at 3-month intervals except for the single-item depression screen by the subjects' research partner. Behavioral changes are significantly more common among patients with Clinical Dementia Rating (CDR) scores of 0.5 compared with CDR scores of 0. Behavioral alterations including irritability, anxiety, and apathy are more common among ethnic minorities than among the White population. Depression, irritability, anxiety, and apathy are significantly correlated with each other.
CONCLUSIONS: Behavioral changes are common among those with mild degrees of cognitive compromise (CDR 0.5). Telephonic assessment of behavioral changes is feasible. The predictive value of these alterations for progression to Alzheimer disease or other dementias will be assessed longitudinally.

Entities:  

Mesh:

Year:  2006        PMID: 17135808     DOI: 10.1097/01.wad.0000213872.17429.0f

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  6 in total

1.  Sample size determination for a matched-pairs study with incomplete data using exact approach.

Authors:  Guogen Shan; Charles Bernick; Sarah Banks
Journal:  Br J Math Stat Psychol       Date:  2017-06-30       Impact factor: 3.380

2.  The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.

Authors:  Clara Li; Judith Neugroschl; Xiaodong Luo; Carolyn Zhu; Paul Aisen; Steven Ferris; Mary Sano
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Developing dementia prevention trials: baseline report of the Home-Based Assessment study.

Authors:  Mary Sano; Susan Egelko; Michael Donohue; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Chung-Kai Sun; Silvia Paparello; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

4.  Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease.

Authors:  Lori Frank; William R Lenderking; Kellee Howard; Marc Cantillon
Journal:  Alzheimers Res Ther       Date:  2011-12-09       Impact factor: 6.982

5.  The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline.

Authors:  Sarah Jane Banks; Rema Raman; Feng He; David P Salmon; Steven Ferris; Paul Aisen; Jeffrey Cummings
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-12-18

6.  Statistical advances in clinical trials and clinical research.

Authors:  Guogen Shan; Sarah Banks; Justin B Miller; Aaron Ritter; Charles Bernick; Joseph Lombardo; Jeffrey L Cummings
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.